Asia Pacific

Refine Search

High-flying BeOne clocks up another Tevimbra EU approval

The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line treatment of adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. 10 July 2025

NICE moves fast on Brukinsa in MCL

BeOne Medicines - the Sino-American oncology specialist formerly known as BeiGene - has announced that the National Institute for Health and Care Excellence (NICE) has recommended Brukinsa (zanubrutinib) to treat relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment. 10 July 2025

Leqembi cost-effectiveness questioned in Japan, as pricing debate intensifies

Japanese authorities are putting Eisai under pressure to reconsider the price of its Alzheimer’s disease therapy Leqembi (lecanemab), after a government-backed review found that the drug significantly exceeds accepted cost-effectiveness thresholds in the country. 10 July 2025

Bayer links up with DKSH on distribution

Singapore-based market expansion services provider DKSH Business Unit Healthcare announced a partnership with Germany’s Bayer. 10 July 2025

JCR in third deal with pharma major

Japan’s JCR Pharmaceuticals closed 15% higher after Wednesday’s trading, as it signed a new licensing deal. 9 July 2025

Taiho suffers setback with DMD hopeful

Shares in Japanese drugmaker Otsuka Holdings closed nearly 2% lower Tuesday, after disappointing clinical trial results from one of its subsidiaries. 8 July 2025

Chugai enters into joint research and license accord with Gero

Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 7 July 2025

Brii Bio signs licensing deal with Joincare Group for antibiotic BRII-693 in China

Chinese biotech Brii Biosciences has licensed its experimental antibiotic BRII-693 to domestic pharma business Joincare Group for development and commercialization in China, as part of a technology transfer and exclusive licensing agreement announced on Wednesday. 4 July 2025

Ceolia takes over from Shionogi in marketing of Actair in Japan

A new company is responsible for Japanese promotional activities for Actair, Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis. 4 July 2025

Challenges mount for big pharma in China as vaccine sales plummet

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China's vaccine market, as regulatory scrutiny, domestic competition, and changing consumer behaviors disrupt a once-thriving sector. 4 July 2025

NICE backs Fruzaqla for NHS use

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Fruzaqla (fruquintinib) be reimbursed by the National Health Service (NHS), Japanese drug major Takeda’s local subsidiary revealed today. 3 July 2025

FDA accelerated approval for Dizal’s sunvozertinib

The US Food and Drug Administration has granted accelerated approval to sunvozertinib (trade name Zegfrovy) from Dizal (Jiangsu) Pharmaceutical for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 3 July 2025

BioVersys joins forces with Shionogi on ansamycin development

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates. 2 July 2025

HanchorBio and Henlius ink deal worth up to $202 million

Taiwanese biotech HanchorBio has signed a licensing agreement with China’s Shanghai Henlius Biotech. 2 July 2025

New owner for Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma Corporation is now under the ownership of US private investment firm Bain Capital Private Equity. 2 July 2025

Adagene and Sanofi extend relationship

Sino-American antibody company Adagene has announced a strategic investment and option exercise by Sanofi. 1 July 2025

FDA approves Takeda’s Gammagard liquid ERC

1 July 2025

Hutchmed wins China approval for Orpathys-Tagrisso combo

Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA). 30 June 2025

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral

Japanese drugmaker Shionogi has filed a supplemental application in Japan to broaden the use of its oral antiviral Xocova (ensitrelvir), aiming to include children as young as six who weigh at least 20 kilograms. 30 June 2025

Dimerix gets first milestone from FUSO Pharma

Australian biotech Dimerix today revealed it has received the first development milestone payment of 400 million yen (~AU$4.2 million; US$2.7 million) from Japan’ FUSO Pharmaceutical, the exclusive licensee of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 30 June 2025

12 3 4 5 6 7 8 9 10 Next page

High-flying BeOne clocks up another Tevimbra EU approval

The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line treatment of adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. 10 July 2025

NICE moves fast on Brukinsa in MCL

BeOne Medicines - the Sino-American oncology specialist formerly known as BeiGene - has announced that the National Institute for Health and Care Excellence (NICE) has recommended Brukinsa (zanubrutinib) to treat relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment. 10 July 2025

Leqembi cost-effectiveness questioned in Japan, as pricing debate intensifies

Japanese authorities are putting Eisai under pressure to reconsider the price of its Alzheimer’s disease therapy Leqembi (lecanemab), after a government-backed review found that the drug significantly exceeds accepted cost-effectiveness thresholds in the country. 10 July 2025

Bayer links up with DKSH on distribution

Singapore-based market expansion services provider DKSH Business Unit Healthcare announced a partnership with Germany’s Bayer. 10 July 2025

JCR in third deal with pharma major

Japan’s JCR Pharmaceuticals closed 15% higher after Wednesday’s trading, as it signed a new licensing deal. 9 July 2025

Taiho suffers setback with DMD hopeful

Shares in Japanese drugmaker Otsuka Holdings closed nearly 2% lower Tuesday, after disappointing clinical trial results from one of its subsidiaries. 8 July 2025

Chugai enters into joint research and license accord with Gero

Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 7 July 2025

Brii Bio signs licensing deal with Joincare Group for antibiotic BRII-693 in China

Chinese biotech Brii Biosciences has licensed its experimental antibiotic BRII-693 to domestic pharma business Joincare Group for development and commercialization in China, as part of a technology transfer and exclusive licensing agreement announced on Wednesday. 4 July 2025

Ceolia takes over from Shionogi in marketing of Actair in Japan

A new company is responsible for Japanese promotional activities for Actair, Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis. 4 July 2025

Challenges mount for big pharma in China as vaccine sales plummet

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China's vaccine market, as regulatory scrutiny, domestic competition, and changing consumer behaviors disrupt a once-thriving sector. 4 July 2025

NICE backs Fruzaqla for NHS use

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Fruzaqla (fruquintinib) be reimbursed by the National Health Service (NHS), Japanese drug major Takeda’s local subsidiary revealed today. 3 July 2025

FDA accelerated approval for Dizal’s sunvozertinib

The US Food and Drug Administration has granted accelerated approval to sunvozertinib (trade name Zegfrovy) from Dizal (Jiangsu) Pharmaceutical for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 3 July 2025

BioVersys joins forces with Shionogi on ansamycin development

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates. 2 July 2025

HanchorBio and Henlius ink deal worth up to $202 million

Taiwanese biotech HanchorBio has signed a licensing agreement with China’s Shanghai Henlius Biotech. 2 July 2025

New owner for Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma Corporation is now under the ownership of US private investment firm Bain Capital Private Equity. 2 July 2025

Adagene and Sanofi extend relationship

Sino-American antibody company Adagene has announced a strategic investment and option exercise by Sanofi. 1 July 2025

FDA approves Takeda’s Gammagard liquid ERC

1 July 2025

Hutchmed wins China approval for Orpathys-Tagrisso combo

Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA). 30 June 2025

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral

Japanese drugmaker Shionogi has filed a supplemental application in Japan to broaden the use of its oral antiviral Xocova (ensitrelvir), aiming to include children as young as six who weigh at least 20 kilograms. 30 June 2025

Dimerix gets first milestone from FUSO Pharma

Australian biotech Dimerix today revealed it has received the first development milestone payment of 400 million yen (~AU$4.2 million; US$2.7 million) from Japan’ FUSO Pharmaceutical, the exclusive licensee of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 30 June 2025

12 3 4 5 6 7 8 9 10 Next page

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze